Common Warts
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
Torii PharmaceuticalVP-102
Torii PharmaceuticalVP-102
Veeva SystemsVP-102
Clinical Trials (3)
Total enrollment: 632 patients across 3 trials
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Start: Jun 2026Est. completion: Jul 2027300 patients
Phase 3Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Start: Dec 2025Est. completion: Jan 2027302 patients
Phase 3Active Not Recruiting
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
Start: Oct 2026Est. completion: Apr 202730 patients
Phase 2Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 632 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.